Ferozsons subsidiary launches human insulin
Company says Ferulin, developed with the highest quality standards, will provide effective and affordable diabetes treatment to patientsÂ
BF Biosciences plans to raise Rs 1.37 billion through IPOÂ
IPO will consist of 25 million ordinary shares with floor price of PKR 55 per share
Searle to sell its entire shareholding in Pakistani subsidiary Â
Board approves sale of 90.61% stake to IJARA-led consortium
Citi Pharma enters into supply agreement with India’s Murli Krishna PharmaÂ
Murli Krishna Pharma will supply high-quality Active Pharmaceutical Ingredients (APIs) and products exclusively to Citi Pharma in Pakistan
CCP approves acquisition of two Japanese pharma products by Hilton Pharma
Proposed transaction entails the acquisition of Methycobal and Myonal including their trademarks
Sales tax hike to 18% expected to raise medicine prices
Sales tax is also imposed on diagnostic kits/equipment across various specialties, including cardiology, neurology, oncology, and urologyÂ
Hoechst Pakistan to acquire products and trademarks from Sanofi affiliates
Board approves strategic acquisition to strengthen product portfolio and market position
Lucky Core seals deal for Pfizer’s Karachi plant, pharma products
Asset Purchase Agreements signed, acquisition includes products such as Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.Â
Searle Company to divest entire stake in Searle Pakistan Limited
Board approves disposal of 100% shareholding; negotiations for terms underway
Lucky Core Industries expands portfolio with Pfizer assets acquisition
Deal includes a manufacturing facility, certain pharma products and trademarks associated with said products
Citi Pharma, Hangzhou Newsea partner to boost local API manufacturing
With an expected annual turnover of Rs15,000m, the JV underscores a push towards reducing import dependence and enhancing local manufacturing infrastructure in Pakistan’s pharmaceutical industry
Saudi investors exit Pakistan’s largest pharmacy chain. What happened and why?
From its origins as part of the Servis Group to multiple changes in ownership since its inception in 2005, Servaid has undergone an eventful two decades in existence
The magic pill for the pharma sector
Will the deregulation in drug pricing policy prove to be the long awaited cure for the pharmaceutical industry?
AGP acquires portfolio of products from American pharma firm Viatris
AGP claims newly acquired products will add Rs20b to annual revenues
PPMA vs DRAP: Pharma crisis continuesÂ
Unavailability of medicines could inevitably trigger national health emergency